Twist Bioscience (TWST) to Release Quarterly Earnings on Thursday

Twist Bioscience (NASDAQ:TWST - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Twist Bioscience to post earnings of ($0.84) per share for the quarter. Twist Bioscience has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties interested in participating in the company's conference call can do so using this link.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The business had revenue of $71.50 million during the quarter, compared to analyst estimates of $67.59 million. During the same period last year, the company earned ($0.74) earnings per share. Twist Bioscience's quarterly revenue was up 31.8% compared to the same quarter last year. On average, analysts expect Twist Bioscience to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Twist Bioscience Stock Up 1.1 %

Shares of TWST traded up $0.33 during midday trading on Thursday, reaching $31.08. 1,234,627 shares of the stock were exchanged, compared to its average volume of 931,222. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -8.61 and a beta of 1.62. Twist Bioscience has a 12-month low of $11.46 and a 12-month high of $43.21. The firm has a 50 day simple moving average of $34.97 and a 200-day simple moving average of $30.32.

Insider Buying and Selling at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the sale, the director now owns 64,169 shares in the company, valued at approximately $2,244,631.62. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, COO Patrick John Finn sold 2,174 shares of the company's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the transaction, the chief operating officer now owns 176,206 shares of the company's stock, valued at $5,307,324.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at $2,244,631.62. The disclosure for this sale can be found here. Insiders sold 13,211 shares of company stock worth $449,573 over the last ninety days. Company insiders own 3.92% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TWST. Scotiabank lifted their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a research note on Monday, February 5th. The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and upped their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Barclays cut their price objective on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 10th.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.